Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Amphastar Pharmaceuticals Inc. (AMPH:NASDAQ), powered by AI.
Amphastar Pharmaceuticals Inc. is currently trading at $19.96. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Amphastar Pharmaceuticals Inc. on Alpha Lenz.
Amphastar Pharmaceuticals Inc.'s P/E ratio is 9.5.
“Amphastar Pharmaceuticals Inc. trades at a P/E of 9.5 (undervalued) with solid ROE of 12.9%. 3Y revenue CAGR of 13.0% highlights clear growth momentum.”
Ask for details →Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to the development, manufacture, and marketing of innovative generic and proprietary injectable, inhalation, and intranasal products. Amphastar's primary function is to provide cost-effective medications that improve patient care and accessibility to treatment. The company’s product portfolio includes critical drugs used in hospitals and other medical settings, targeting areas like endocrinology, anesthesia, and pain management. Amphastar Pharmaceuticals impacts the healthcare industry significantly by supplying generic alternatives to high-cost brand-name drugs, greatly aiding healthcare systems in managing medication expenditures. Headquartered in Rancho Cucamonga, California, Amphastar operates both in the United States and internationally, emphasizing rigorous quality control and regulatory compliance in its production processes. The company plays a vital role in the healthcare market by ensuring a steady supply of essential medicines, helping to alleviate shortages and support the delivery of efficient medical care.
“Amphastar Pharmaceuticals Inc. trades at a P/E of 9.5 (undervalued) with solid ROE of 12.9%. 3Y revenue CAGR of 13.0% highlights clear growth momentum.”
Ask for details →Amphastar Pharmaceuticals Inc. (ticker: AMPH) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,028 employees. Market cap is $933M.
The current price is $19.96 with a P/E ratio of 9.51x and P/B of 1.18x.
ROE is 12.90% and operating margin is 19.50%. Annual revenue is $720M.